1 Terry Moore, B.Sc., M.Sc., PhD. (abd) 24 years experience of - - PowerPoint PPT Presentation

1

Terry Moore, B.Sc., M.Sc., PhD. (abd)

• 24 years experience of treating chronic and recurrent

pain based upon discoveries during his PhD studies at the University of Guelph

• Terry Moore developed the Myo

yoWo WorxIntegrated Treatment Program

• Moore’s clinic, MMTR Health Inc., is located in Guelph,

Ontario.

2

MMTR Health Inc.

The MyoWo Worx  Integrated Treatment Program is a muscle relaxation and restoration treatment based proprietary technology initially aimed at treating patients with chronic and recurring pain. Today, MMTR treats many referred patients with various

• ther pathological conditions that have not responded to

conventional therapies.

3

The My MyoWor

• rx Treatment Program is comprised of 3 parts:
• 1. Individual Patient Assessment
• 2. Muscle Relaxation/Restoration Treatment using the

Proprietary TM20 muscle relaxation device. Data strongly suggest it restores function to blood vessels, muscles and nerves

• 3. A Tailored Exercise Program

My MyoWorx

TM TM

Integrated Treatment for Chronic and Recurring Pain

4

• Detailed focused history
• Examination of symptom areas
• Identifies need for ancillary laboratory tests
• Assessment of contributory factors

Individual Patient Assessment

5

My MyoWorx

TM TM

My MyoWorx

TM TM

Treatment Rationale

Increased tension, painful spasm, fatigue or injury of the muscles supporting the spine can cause pressure on the spinal nerves as well as other paraspinal tissues and structures. As a result, one can experience:

• pain, tingling or numbness
• altered functioning of muscles
• secondary effects on organs

Unresolved, numerous muscle and joint injuries, chronic or recurring pain and neurological and other physical symptoms can perpetuate

6

My MyoWorx

TM TM TM20 Device

How it works

• A patented device that delivers a sequence of electrical

frequencies in a timed manner to the paraspinal structures.

• Pre-clinical studies showed these frequencies can:
• Re-establish normal resting membrane potentials in the

cells of fatigued or injured muscles

• Evoke CNS activity that facilitates muscle relaxation;

long-term effect

• Produce increases in blood flow via smooth muscle

relaxation leading to restoration of oxygen and nutrient uptake

7

Results in improvement of:

• Muscle function
• Better ability to stretch and maintain optimal muscle

fiber length resulting in increased muscle strength and endurance

• Blood flow
• Breaks the cycle of vasoconstriction
• Increases vascular perfusion

Cannot be achieved by stretching and strengthening exercises alone

My MyoWorx

TM TM TM20 Device

8

FDA Approved as a ‘Electronic Muscle Exerciser’: April 1982

Labeling as follows:

• 1. Relaxation of muscle spasm
• 2. Prevention of retardation of tissue atrophy
• 3. Increasing local blood circulation
• 4. Muscle-re-education
• 5. Immediate postsurgical stimulation of calf muscles to prevent

venous thrombosis

• 6. Maintaining of increasing range of motion

My MyoWorx TM20 Device

9

My MyoWorx TM2 TM20 De Devic ice

Why is the TM20 different from?

• Transcutaneous Electrical Nerve Stimulation (TENS),

Interferential Current (IFC), or Muscle Stimulation

• TENS/IFC manage pain via direct nerve stimulation
• Increase blood flow and muscle relaxation through varying

degrees of electrically-induced muscle contraction

• usually a short term effect
• TM20 patented technology aims directly at reducing the

underlying muscle spasm and relieves the associated pathologies

• f both neurological and micro-vasculature structures
• potentially long term sustainable results

10

• Moderate home-based stretching and strengthening exercises

aimed at ‘re-educating’ the musculature

• Essential to providing long-term benefit
• Educates and empowers the patient to manage symptoms
• Reduces emotional impact
• Creates awareness of external factors

e.g., barometric pressure effects

My MyoWorx

TM

Targeted Exercise and Symptom Management Strategies

11

My MyoWorx

TM Pro

rogra ram

Clinical Data on Chronic and Recurring Pain

12

• Consecutive patients treated over a 10 year period
• Data analysis Group: N=518 including 32 patients with

associated anxiety and/ or depression

• All patients received the MyoWorx treatment program
• MMTR recorded additional outcomes to determine the

effects of the MyoWorxMuscle Relaxation/Restoration Treatment and Targeted Exercise on associated conditions

My MyoWorx

TM Program

am

Clinical Dat Data a on

• n Chr

hroni

• nic and

and Recur urring Pai ain

13

Patient Characteristics

• All patients presented with chronic and recurring pain many of

whom, in retrospect, had referred pain syndromes

• Presentation of pain: arthritis, migraine headaches, motor

vehicle accidents, occupational origins including repetitive strain injuries

• Pain location: head, trunk and limbs
• Prior therapies included: medications, nerve block, traditional

physiotherapy, TENS, acupuncture, chiropractic, and registered massage therapy

My MyoWorx

TM Pro

rogra ram

Clinical Dat Data a on

• n Chr

hroni

• nic and

and Recur urring Pai ain

14

Methodology

• The degree of pain in all patients was assessed using the Borg

Pain Scale (0 to 10; 10 being most severe)

• Patients pain levels were recorded before and after each

treatment

• Symptoms of tingling or numbness were also graded on a

similar scale

• Anatomical location of pain, anaesthesia or paraesthesia were

categorized as cervical, trapezius, thoracic, lumbar and sacral

My MyoWorx

TM Pro

rogra ram

Clinical Dat Data a on

• n Chr

hroni

• nic and

and Recur urring Pai ain

15

Methodology (continued)

• Results were grouped as percent reduction in overall pain

score:

My MyoWorx

TM Pro

rogra ram

Clinical Dat Data a on

• n Chr

hroni

• nic and

and Recur urring Pai ain

16

Category % Reduction in Pain Level Poor 0-30% Moderate 30-70% Excellent > 70%

Pain Response by Anatomical Site

(does not include response of referred pain syndromes)

My MyoWorx

TM Pro

rogra ram

Clinical Dat Data a on

• n Chr

hroni

• nic and

and Recur urring Pai ain

17

Anatomical Site Percentage Sustained Reduction in Pain Score

Overall Response (n=518) No Diagnosed Psychological Disorder (n= 486) Associated Depression

• r Anxiety Disorder

(n=32)

Cervical 76% 80% 0% Trapezius 76% 81% 0% Thoracic 79% 85% 0% Lumbar 80% 85% 0% Sacral 78% 83% 0%

Response Rates

• When there was an associated referred pain syndrome (most cases),

this symptom was abolished in over 90% of instances

• When the response of the associated referred pain syndrome is

included in the total response rate, the percentages of responders

• increased. For example, a patient presenting with sciatica may

experience complete resolution of associated pain in the lumber, hip, hamstring, knee and calf areas.

My MyoWorx

TM Pro

rogra ram

Clinical Dat Data a on

• n Chr

hroni

• nic and

and Recur urring Pai ain

18

Anatomical Site Referred Pain Sites Pre- treatment Post- treatment % reduction in pain Sciatica/ Lumbar 4 1 75% Hip 8 100% Hamstring 8 100% Knee 8 100% Calf 8 100% 95% (overall)

19

2.9% 2.3% 3.4%

6.9% 9.5% 5.1%

90.2% 88.0% 91.6% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Total (n = 518) Male (n = 222) Female ( n = 296) Successful Recovery

Total Responders: Males vs. Females

Poor Moderate Excellent

20

1.9% 3.4% 5.0% 7.8%

93.1% 88.8%

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Acute (n = 160) Chronic (n = 358) Successful Recovery

Total Responders: Acute vs. Chronic

Poor Moderate Excellent

21

3.3% 2.4% 6.5% 7.6% 90.0% 90.0% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Prev Ther (n = 307) No Prev Ther (n=211) Successful Recovery

Previous vs. No Previous Therapy

Poor Moderate excellent

22

3.0% 5.0% 1.1% 2.3% 0.0% 8.3%

6.7% 2.5% 9.2% 7.0% 0.0% 0.0%

90.2% 92.5% 89.7% 90.1% 100.0% 92.7% 0% 20% 40% 60% 80% 100% 120% Occ (n=167) Occ Female (n=80) Occ Male (n=87) Occ Lin (n=128) Occ Blount (n=9) Occ GGH (n=12) Successful Recovery

Occupational Recovery

Poor Moderate Excellent

23

0%

2.2% 4.6%

2.2% 2.2%

6.9% 0.0%

0% 5.60% 6.90% 7.40% 5.50% 6.90% 16.7% 100% 92.1% 88.5% 90.4% 92.3% 86.0% 83.3% 0% 20% 40% 60% 80% 100% 120% 10-19 (n=14) 20-29 (n=89) 30-31 (n=131) 40-49 (n=135) 50-59 (n=91) 60-69 (n=29) 70+ (n = 18)

Age and Recovery

Poor Moderate Excellent

Key Findings

• The My

MyoWo Worx program has a high success rate in

relieving acute and chronic pain of multiple origins

• All age groups benefit from treatment
• Outcome is not dependent on prior therapy

My MyoWorx

TM Program

am Clinical Results on Chronic and Recurring Pain

24

Therapy had a Major Effect on Work Disability

• After treatment, absenteeism and work disability due to pain

were reduced for at least 6 months

• Patients with low back injuries and repetitive strain injuries:
• treated promptly were able to continue working

(e.g., Carpal Tunnel Syndrome)

• if on disability were able to return to work soon after

initiating therapy

• In all responders the pain was durably reduced for at least 2

months

My MyoWorx

TM Program

am Clinical Results on Chronic and Recurring Pain

25

Unexpected Additional Benefits Observed (requiring further study)

• Relief of:
• neuropathy symptoms (e.g., trigeminal neuralgia)
• Myo-fascial pain (e.g., plantar fasciitis)
• Accelerated healing of wounds (e.g., diabetic foot ulcer)
• Reduction of excessive urinary frequency and urgency

My MyoWorx

TM M Program

am Clinical Data on Chronic and Recurring Pain

26

27

Myo yoWo Worx Wo Works